RMTG · Regenerative Medical Technology Group Inc.
$0.04
+0.00 (+6.38%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since inception, resulting in an accumulated deficit of approximately $79,484,265 and a working capital deficit of $40,328,417 as of June 30, 2026, and future losses are anticipated. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Market Cap
$548,184
Shares
13.74M
Volume · Oct 20
1500
Avg daily vol (3M)
64.98K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.04
Open$0.04
Day$0.04–0.04
52W close$0.02–0.12
Avg vol 30d49K
Short int9K · 0.1% float · 1.0d
Short vol100%
DataJan 2020–Oct 2026
Filing10-Q · Aug 19
Up next
filed Aug 19, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$9.41M
Trailing 12 months
Net income (TTM)
−$9.39M
Trailing 12 months
Revenue growth YoY
+309.1%
Year over year
Operating margin
0.5%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+5.5%
Year over year · more shares
Price change (1Y)
-27.3%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−42%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
21%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−55%
trailing
6-month return
−5%
trailing
YTD return
−18%
this year
Relative strength
−13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.06% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
26
low risk · 0–100
Fundamentals
Revenue growth
+24%
Y/Y
Gross margin
55%
contracting
EPS growth
−41%
Y/Y
Free cash flow
$-1.3M
Quant / Vol
risk profile
Volatility
372%
annualized · 1-yr
Max drawdown
−74%
past year
ATR
17.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−42%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
21%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.06% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 21%
Range high $0
vs 200-day avg -24%
vs 50-day avg -42%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| First quarter of 2026 revenue increase compared with the fourth quarter of 2025 | 69% | first quarter of 2026 compared with the fourth quarter of 2025 filing | — |
| Second quarter of 2026 revenue increase compared with the fourth quarter of 2025 | 1.66% | second quarter of 2026 compared with the fourth quarter of 2025 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RMTG
this stock
Regenerative Medical Technology Group Inc.
|
$548,184 | -18.4% | +24.2% | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RMTG | -16.3% | -54.8% | -4.8% | -30.4% | -18.4% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -15.2% | -54.2% | -12.8% | -31.3% | -31.2% |